DURHAM, N.C., November 5, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced the appointment of Jason Mieding to the role of Chief Operating Officer (COO), a newly created position that reflects the growth of the organization over the past 22 months.
As COO, Jason will serve as site head for MedPharm’s state-of-the-art semisolid manufacturing facility, overseeing operational strategy, execution, and performance while contributing to strategic planning, capital allocation, organizational development, and company culture. He brings extensive experience in pharmaceutical manufacturing and operations, having held positions of increasing responsibility at Thermo Fisher Scientific and Patheon.
“I’m excited to be joining MedPharm at such an important time in the company’s history,” commented Jason Mieding, Chief Operating Officer, MedPharm. “The company has a strong reputation for its expertise and commitment to operational excellence, and I look forward to working with the team to build on this foundation, drive continuous improvement, delight our customers, and support the company’s continued growth.”
“We are delighted to welcome Jason to the team. His track record in commercial pharmaceutical manufacturing and operational excellence will be a real asset to MedPharm as our growth accelerates and we continue to invest in strengthening our capabilities,” said Bill Humphries, Chief Executive Officer, MedPharm. “His leadership will be important in supporting our team and ensuring we continue to deliver for our customers.”
About MedPharm
MedPharm is an end-to-end contract service provider of topical and transepithelial products supporting early-phase research, formulation development and in vitro testing services in addition to both clinical and commercial manufacturing. With its 2024 merger with Tergus Pharma, MedPharm enhanced its capabilities, transforming the business into a truly differentiated CDMO of scale with superior end-to-end capabilities from drug development and formulation to large batch commercial manufacturing and distribution.
For more than 25 years, MedPharm has specialized in reducing risk through its unique, industry-leading in vitro testing and research biology models and is a global leader in product development for dermal/transdermal, lung and nasal, mucosal membrane, ungual, otic, and ophthalmic delivery. MedPharm has locations in the United Kingdom and the United States, including a new 110,000 sq. ft. state-of-the-art manufacturing facility in Durham, North Carolina. For more information, visit medpharm.com or follow us on LinkedIn.
Media Contacts:
Sadie Smith, Marketing and Events Coordinator
Miles Fisher-Pollard, Orientation Marketing
